Aviv Scientific

Company Overview

Snapshot

Founded in July 2017 by Shai Efrati, Jonathan Preminger, and Michael Lobel, Aviv Scientific operates with 11–50 employees. The company has raised $62 million across two funding rounds. In September 2021, Aviv Scientific secured a funding round from investors.

Business overview

Aviv Scientific specializes in addressing age-related cognitive and functional decline through novel applications of hyperbaric medicine. The company aims to enhance cognitive and physical performance in healthy aging adults by leveraging an exclusive global partnership with the Sagol Center at Shamir Medical Center in Israel. Aviv Scientific is establishing a worldwide network of medical clinics that integrate hyperbaric oxygen therapy (HBOT) with personalized programs of cognitive and physical training, serving markets in the United States and United Arab Emirates within the Health Tech & Life Sciences sector.

Strategic signal

In March 2023, Aviv Clinics highlighted a new study demonstrating the positive impact of hyperbaric oxygen therapy on fibromyalgia patients. This research underscores the company's ongoing commitment to validating its treatment protocols through scientific evidence, signaling potential for broader application and market acceptance of its hyperbaric medicine solutions for various conditions.

Company Intelligence Q&A

What is Aviv Scientific's primary focus?

Aviv Scientific focuses on treating age-related cognitive and functional decline, utilizing hyperbaric medicine to enhance human performance and improve the aging process in healthy adults.

When was Aviv Scientific founded?

Aviv Scientific was founded in July 2017 by Shai Efrati, Jonathan Preminger, and Michael Lobel.

What was a significant finding published in November 2020?

In November 2020, a human study showed a reversal in the biology of aging, specifically telomere shortening and senescent cell accumulation, through hyperbaric oxygen therapy (HBOT).

What was the focus of a study highlighted by Aviv Clinics in February 2022?

In February 2022, Aviv Clinics highlighted a study indicating that hyperbaric oxygen therapy can improve symptoms and brain structure in veterans suffering from treatment-resistant PTSD.

What was the outcome of the first Long COVID clinical trial presented by Aviv Clinics and Sagol Center in August 2022?

In August 2022, Aviv Clinics and the Sagol Center for Hyperbaric Medicine and Research presented research findings from the first Long COVID clinical trial to show symptom relief.